中风患者福音:澳洲研究团队研发中风新疗法,大幅提高康复水平

2018-02-01 Lily 来宝网

只吃盘子右边的食物,刮胡子或者把化妆品涂到脸的一边是中风后的常见症状,对于一些幸存者来说,目前的疗法是行不通的。昆士兰大学的研究人员正在领导一项世界第一项目,该项目可能有助于克服影响中风幸存者许多日常活动的残疾。

新疗法为中风恢复提供了希望】只吃盘子右边的食物,刮胡子或者把化妆品涂到脸的一边是中风后的常见症状,对于一些幸存者来说,目前的疗法是行不通的。昆士兰大学的研究人员正在领导一项世界第一项目,该项目可能有助于克服影响中风幸存者许多日常活动的残疾。

昆士兰大学人体运动与营养科学研究员将探讨一种新的疗法,通过机器指导手训练中风幸存者的大脑。“神经心理状态被称为空间忽略,通常发生在大脑右半球受损后,这使得中风幸存者很难注意空间的左侧”。

高达85%的右半球卒中幸存者对空间左侧的能力下降,这可能影响到许多活动。他们可能会与物体或结构发生碰撞,比如左边的门框。目前,对空间忽略的人没有满意的治疗方法。目前的一种治疗方法是在佩戴带有棱镜的眼镜的同时,将整个视野移向右侧。为了准确地佩戴棱镜眼镜,空间忽略的人必须学会在被忽视的方面达到目标。

对于不同的病人,治疗的效果会有很大的不同,从一个疗程后长期的功能改善到根本没有益处。“我们正在测试一种新的方法,在这种方法中,我们使用机器人,在人手到达时将身体推向一侧,而不是用棱镜来扭曲视力”。

“我们希望证明,当机器人将手推向一侧时,学会移动直线,有助于人们更好地将注意力转移到空间的左侧。这将有助于我们更好地理解中风后注意力和运动之间的联系,并可能为将来有注意力缺陷的脑中风幸存者带来新的康复方法。”

中风基金会的数据显示,超过475000澳大利亚人受到了中风的影响,这个数字在2050年预计将上升到一百万。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677035, encodeId=d80b16e7035a8, content=<a href='/topic/show?id=206366e4077' target=_blank style='color:#2F92EE;'>#澳洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66740, encryptionId=206366e4077, topicName=澳洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8d027423047, createdName=huangdf, createdTime=Mon Apr 16 18:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300114, encodeId=052513001141c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538071, encodeId=53b915380e158, content=<a href='/topic/show?id=e835226210e' target=_blank style='color:#2F92EE;'>#中风患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22621, encryptionId=e835226210e, topicName=中风患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b5612933772, createdName=sunylz, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554523, encodeId=1be1155452332, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570048, encodeId=59f915e0048b2, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-04-16 huangdf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677035, encodeId=d80b16e7035a8, content=<a href='/topic/show?id=206366e4077' target=_blank style='color:#2F92EE;'>#澳洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66740, encryptionId=206366e4077, topicName=澳洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8d027423047, createdName=huangdf, createdTime=Mon Apr 16 18:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300114, encodeId=052513001141c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538071, encodeId=53b915380e158, content=<a href='/topic/show?id=e835226210e' target=_blank style='color:#2F92EE;'>#中风患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22621, encryptionId=e835226210e, topicName=中风患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b5612933772, createdName=sunylz, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554523, encodeId=1be1155452332, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570048, encodeId=59f915e0048b2, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-03 lqvr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677035, encodeId=d80b16e7035a8, content=<a href='/topic/show?id=206366e4077' target=_blank style='color:#2F92EE;'>#澳洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66740, encryptionId=206366e4077, topicName=澳洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8d027423047, createdName=huangdf, createdTime=Mon Apr 16 18:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300114, encodeId=052513001141c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538071, encodeId=53b915380e158, content=<a href='/topic/show?id=e835226210e' target=_blank style='color:#2F92EE;'>#中风患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22621, encryptionId=e835226210e, topicName=中风患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b5612933772, createdName=sunylz, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554523, encodeId=1be1155452332, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570048, encodeId=59f915e0048b2, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677035, encodeId=d80b16e7035a8, content=<a href='/topic/show?id=206366e4077' target=_blank style='color:#2F92EE;'>#澳洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66740, encryptionId=206366e4077, topicName=澳洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8d027423047, createdName=huangdf, createdTime=Mon Apr 16 18:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300114, encodeId=052513001141c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538071, encodeId=53b915380e158, content=<a href='/topic/show?id=e835226210e' target=_blank style='color:#2F92EE;'>#中风患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22621, encryptionId=e835226210e, topicName=中风患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b5612933772, createdName=sunylz, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554523, encodeId=1be1155452332, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570048, encodeId=59f915e0048b2, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-03 kcb074
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677035, encodeId=d80b16e7035a8, content=<a href='/topic/show?id=206366e4077' target=_blank style='color:#2F92EE;'>#澳洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66740, encryptionId=206366e4077, topicName=澳洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8d027423047, createdName=huangdf, createdTime=Mon Apr 16 18:10:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300114, encodeId=052513001141c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538071, encodeId=53b915380e158, content=<a href='/topic/show?id=e835226210e' target=_blank style='color:#2F92EE;'>#中风患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22621, encryptionId=e835226210e, topicName=中风患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b5612933772, createdName=sunylz, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554523, encodeId=1be1155452332, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570048, encodeId=59f915e0048b2, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Sat Feb 03 03:10:00 CST 2018, time=2018-02-03, status=1, ipAttribution=)]

相关资讯

Stroke Vas Neur:中风治疗:这种中药加阿司匹林可以极大改善脑功能!

一项新的研究表明,当与阿司匹林联合使用时一种被称为银杏叶的古老草本植物提取物可能有益于中风后的认知功能。

Stem Cell Rep:aPKC-CBP信号通路参与调节中风后神经血管的重塑和功能恢复!

科学家的研究表明非典型的蛋白激酶C(atypical protein kinase C,aPKC)介导在CREB-结合蛋白中S436的磷酸化,它在发育和老年大脑中调节神经前体细胞的分化。中风后的神经血管重塑过程中aPKC介导CREB结合蛋白磷酸化。

NEJM:中风6-16h依据灌注显像选择进行脑血栓切除术

研究认为,对于中风后6-16小时,脑近端中动脉或颈内动脉闭塞,组织区域缺血但尚未梗死的患者,接受血管内血栓切除联合药物治疗的效果优于单纯性药物治疗

BMJ:每天1支烟也会大幅提高中风及冠心病风险

研究发现,每天仅吸1支烟导致的冠心病和中风风险之高,大大超乎人们的预料。对于心脑血管疾病而言,不存在安全的吸烟水平。吸烟者应该戒烟,而不是减少吸烟,以降低常见心脑血管病疾病风险

NEJM:中风后6-24小时的晚期血栓切除可改善临床症状与梗死体积不匹配患者预后

研究认为,对于急性缺血性中风发作6-24小时,临床症状与梗死体积不匹配的患者,接受血管内血栓切除可改善预后,降低致残率

NEJM:KRAS激活突变导致脑动静脉畸形

研究发现脑动静脉畸形组织样本中存在KRAS激活突变,提示上述畸形是由KRAS诱导的脑内皮细胞MAPK-Erk信号通路激活所致